• Development of an AI-Agent for Urological Disease Diagnosis and Treatment

  NCT07721935

  RecruitingObservationalUpdated Jul 23, 2026
• Evaluation of AI Large Models for Diagnosis and Treatment in Real-World Cases: Multicenter Retrospective Study

  NCT07378358

  RecruitingObservationalUpdated Jan 30, 2026
• Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer

  NCT07095751

  Not yet recruitingInterventionalNot ApplicableUpdated Jul 22, 2026
• Human Doctors or AI: Evaluating Patient Satisfaction in Urinary Stone Disease Consultations

  NCT07111845

  CompletedInterventionalNot ApplicableUpdated Aug 8, 2025
• Robot-assisted Urological Surgeries Using the MicroHand S Robot

  NCT05462392

  Unknown statusInterventionalNot ApplicableUpdated Aug 2, 2023
• The Efficacy and Safety of Chinese Domestic Surgical Robot System in Urological Telesurgery

  NCT05739812

  Unknown statusInterventionalNot ApplicableUpdated Jul 14, 2023

ClinicalTrials.gov ID

NCT07555756

Lead Sponsor

First Affiliated Hospital of Guangxi Medical UniversityOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

1,080Estimated

Last Update Posted

Apr 29, 2026Actual

Start Date

May 1, 2026Estimated

Primary Completion Date

Apr 30, 2029Estimated

Completion Date

Jul 31, 2029Estimated

Official Title

AN INTERNATIONAL MULTICENTER CLINICAL STUDY ON APPLICATION OF UROMED AI DOCTOR BASED ON LARGE LANGUAGE MODELS

Brief Summary

This study evaluates our team's urology-specific AI (UroMed AI Doctor) for its safety, professionalism, knowledge and Q&A ability, and tests its effectiveness against traditional manual urology care, to confirm if it can be a safe auxiliary tool and improve patients' preoperative experience.

Before the study, we will test the AI with urology questions, compare it to international AI models (DeepSeek, ChatGPT, Google Gemini), and have two senior chief physicians evaluate it.

In the clinical trial, patients at The First Affiliated Hospital of Guangxi Medical University will be randomly split into two groups: AI-assisted care or traditional care by a specialist.

Two senior specialists will evaluate both groups blindly; each group will get preoperative education (AI or physician), with anxiety and satisfaction surveyed.

Subsequently, a multi-center validation will be conducted with 11 domestic and international hospitals.

Detailed Description

Prior to the clinical study, the knowledge base, Q&A capability, professionalism, and safety of the urology UroMed AI Doctor independently developed by our team will be evaluated. The evaluation method involves using the UroMed AI Doctor for public science Q&A and answering standard urology examination questions (multiple-choice and case analysis questions). Comparisons will be made with internationally recognized large language models such as DeepSeek, ChatGPT, and Google Gemini. Two senior chief physicians will conduct the evaluation based on a scoring rubric. In the clinical study phase, trial cases will first be recruited at the lead institution, The First Affiliated Hospital of Guangxi Medical University. Enrolled patients will be randomly assigned to either the UroMed AI Doctor-assisted diagnosis and treatment group or the traditional manual diagnosis and treatment group. The scope of UroMed AI Doctor assistance includes providing auxiliary diagnosis and treatment plans based on the admission records of urology inpatients. The traditional manual group will have these tasks completed by one specialist attending physician. The evaluation will be independently conducted by two senior chief specialists using a blinded method. Furthermore, the UroMed AI Doctor and the attending physician will respectively provide preoperative science education to patients within their groups. The post-education anxiety reduction and satisfaction levels of patients in both groups will be compared using survey scales. Subsequently, a multi-center clinical validation was conducted in collaboration with 11 clinical research centers both domestically and internationally, including Guilin People's Hospital, Yulin Red Cross Hospital, Liuzhou Hospital of Traditional Chinese Medicine, Guigang People's Hospital, Nanning Second People's Hospital, Affiliated Hospital of Youjiang Medical University for Nationalities, Beihai People's Hospital, as well as Binh Duong General Hospital, Hue Central Hospital, Viet Duc Hospital, and the University of Medicine and Pharmacy at Ho Chi Minh City in Vietnam.

• Kidney Calculi
• Prostatic Hyperplasia
• Urinary Bladder Neoplasms

• UroMed AI Doctor-assisted Urological Diagnosis, Treatment and Preoperative Health Education
• Physician-led Urological Diagnosis, Treatment & Preoperative Education

Ages Eligible for Study

Adult (18-64)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Diagnosed with kidney stones, benign prostatic hyperplasia, or bladder cancer in line with the Chinese Guidelines for the Diagnosis and Treatment of Urological and Andrological Diseases (2022 Edition) and requiring hospitalization for surgery.

Aged 18 to 60 years with good communication skills. Voluntarily agrees to participate in the clinical study and has signed the informed consent form.

Exclusion Criteria:

• Suffers from psychiatric disorders. Refuses to participate in medical activities involving the use of artificial intelligence systems.

Unable to engage in effective communication with the research team. Has multiple underlying diseases with unstable clinical conditions.

Primary Purpose

Diagnostic

Allocation

Randomized

Interventional Model

Parallel Assignment

Masking

Single

Lead Sponsor

First Affiliated Hospital of Guangxi Medical UniversityOTHER

ttloan@hueuni.edu.vn+84315968714

phamnhuhiepdr@gmail.com+84902453258